Rapid Micro Biosystems, Inc. Financials
This page shows Rapid Micro Biosystems, Inc. (RPID) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Rapid Micro Biosystems, Inc. has an operating margin of -178.0%, meaning the company retains $-178 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -251.2% the prior year.
Rapid Micro Biosystems, Inc.'s revenue surged 24.6% year-over-year to $28.1M, reflecting rapid business expansion. This strong growth earns a score of 99/100.
Rapid Micro Biosystems, Inc. carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.61, Rapid Micro Biosystems, Inc. holds $4.61 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Rapid Micro Biosystems, Inc. generated -$44.2M in operating cash flow, capex of $1.4M consumed most of it, leaving -$45.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Rapid Micro Biosystems, Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Rapid Micro Biosystems, Inc. generates $0.94 in operating cash flow (-$44.2M OCF vs -$46.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Rapid Micro Biosystems, Inc. generated $28.1M in revenue in fiscal year 2024. This represents an increase of 24.6% from the prior year.
Rapid Micro Biosystems, Inc.'s EBITDA was -$46.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 12.9% from the prior year.
Rapid Micro Biosystems, Inc. generated -$45.5M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 3.0% from the prior year.
Rapid Micro Biosystems, Inc. reported -$46.9M in net income in fiscal year 2024. This represents an increase of 10.6% from the prior year.
Rapid Micro Biosystems, Inc. earned $-1.08 per diluted share (EPS) in fiscal year 2024. This represents an increase of 11.5% from the prior year.
Rapid Micro Biosystems, Inc. held $16.9M in cash against $0 in long-term debt as of fiscal year 2024.
Rapid Micro Biosystems, Inc.'s operating margin was -178.0% in fiscal year 2024, reflecting core business profitability. This is up 73.2 percentage points from the prior year.
Rapid Micro Biosystems, Inc.'s net profit margin was -167.2% in fiscal year 2024, showing the share of revenue converted to profit. This is up 65.8 percentage points from the prior year.
Rapid Micro Biosystems, Inc. invested $14.6M in research and development in fiscal year 2024. This represents an increase of 13.9% from the prior year.
Rapid Micro Biosystems, Inc. invested $1.4M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 26.0% from the prior year.
RPID Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.8M+7.9% | $7.3M+0.8% | $7.2M+13.7% | $6.3M+3.1% | $6.1M+22.9% | $5.0M-0.7% | $5.0M+15.1% | $4.4M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $3.5M+9.3% | $3.2M-10.9% | $3.6M+9.2% | $3.3M+6.5% | $3.1M-3.6% | $3.2M+2.5% | $3.2M-7.3% | $3.4M |
| SG&A Expenses | $5.6M-7.2% | $6.1M+6.8% | $5.7M+2.8% | $5.5M-10.8% | $6.2M-7.8% | $6.7M+4.0% | $6.5M-9.3% | $7.1M |
| Operating Income | -$11.4M+6.4% | -$12.1M-4.2% | -$11.7M+4.3% | -$12.2M+15.6% | -$14.4M+4.0% | -$15.1M-1.2% | -$14.9M+13.8% | -$17.3M |
| Interest Expense | $393K | N/A | $983K-5.6% | $1.0M-4.8% | $1.1M+1.9% | $1.1M+7.0% | $1.0M-15.1% | $1.2M |
| Income Tax | $8K-27.3% | $11K+57.1% | $7K-12.5% | $8K-20.0% | $10K+66.7% | $6K-14.3% | $7K0.0% | $7K |
| Net Income | -$11.5M+3.0% | -$11.9M-5.3% | -$11.3M-0.8% | -$11.2M+16.6% | -$13.4M+4.5% | -$14.0M-0.9% | -$13.9M+15.6% | -$16.4M |
| EPS (Diluted) | $-0.26+3.7% | $-0.27-3.8% | $-0.260.0% | $-0.26+16.1% | $-0.31+6.1% | $-0.33-3.1% | $-0.32+17.9% | $-0.39 |
RPID Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $84.4M+11.7% | $75.6M-11.5% | $85.4M-40.4% | $143.5M-4.5% | $150.2M-6.7% | $160.9M-7.1% | $173.3M-9.1% | $190.7M |
| Current Assets | $70.0M+16.3% | $60.1M-13.1% | $69.2M-42.5% | $120.4M+4.7% | $115.0M-13.3% | $132.7M+2.8% | $129.1M-6.8% | $138.6M |
| Cash & Equivalents | $18.9M+3.3% | $18.3M-3.0% | $18.9M-22.1% | $24.3M+2.1% | $23.8M-17.1% | $28.7M+17.5% | $24.4M-9.8% | $27.1M |
| Inventory | $21.1M+2.5% | $20.6M-0.8% | $20.7M+3.8% | $20.0M-1.1% | $20.2M-3.6% | $20.9M0.0% | $20.9M-1.1% | $21.2M |
| Accounts Receivable | $5.4M-10.2% | $6.0M+33.8% | $4.5M-18.3% | $5.5M+41.6% | $3.9M+13.0% | $3.5M-37.3% | $5.5M+2.6% | $5.4M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $40.1M+90.5% | $21.0M+5.5% | $19.9M-21.7% | $25.5M+13.8% | $22.4M+5.0% | $21.3M+2.3% | $20.8M-21.3% | $26.5M |
| Current Liabilities | $16.5M+0.9% | $16.4M+9.4% | $15.0M-21.0% | $19.0M+21.6% | $15.6M+8.3% | $14.4M+5.5% | $13.7M-28.3% | $19.1M |
| Long-Term Debt | $18.8M | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| Total Equity | $44.3M-18.7% | $54.5M-16.7% | $65.5M-44.5% | $118.0M-7.7% | $127.8M-8.5% | $139.6M-8.4% | $152.4M-7.1% | $164.2M |
| Retained Earnings | -$509.9M-2.3% | -$498.4M-2.4% | -$486.5M-13.6% | -$428.4M-2.7% | -$417.2M-3.3% | -$403.8M-3.6% | -$389.8M-3.7% | -$375.9M |
RPID Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.1M+6.7% | -$9.7M-7.0% | -$9.1M+4.5% | -$9.5M+2.2% | -$9.7M-5.6% | -$9.2M+44.9% | -$16.7M-43.2% | -$11.7M |
| Capital Expenditures | $73K-80.1% | $366K+14.7% | $319K-23.7% | $418K-7.7% | $453K+110.7% | $215K-71.7% | $759K-6.4% | $811K |
| Free Cash Flow | -$9.1M+9.4% | -$10.1M-7.3% | -$9.4M+5.4% | -$9.9M+2.4% | -$10.2M-8.0% | -$9.4M+46.1% | -$17.4M-39.9% | -$12.5M |
| Investing Cash Flow | -$9.6M-202.6% | $9.3M-12.5% | $10.7M+6.7% | $10.0M+110.0% | $4.8M-64.6% | $13.5M-3.2% | $13.9M+8.7% | $12.8M |
| Financing Cash Flow | $19.2M+6558.7% | -$298K-178.6% | $379K+3258.3% | -$12K-125.0% | $48K+633.3% | -$9K-107.4% | $122K+40.2% | $87K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RPID Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -145.1%+22.2pp | -167.3%-5.4pp | -161.8%+30.5pp | -192.3%+42.8pp | -235.1%+65.8pp | -301.0%-5.6pp | -295.4%+99.2pp | -394.6% |
| Net Margin | -146.8%+16.5pp | -163.3%-7.0pp | -156.3%+20.0pp | -176.3%+41.6pp | -217.9%+62.3pp | -280.2%-4.4pp | -275.8%+100.2pp | -376.0% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -13.6%+2.1pp | -15.7%-2.5pp | -13.2%-5.4pp | -7.8%+1.1pp | -8.9%-0.2pp | -8.7%-0.7pp | -8.0%+0.6pp | -8.6% |
| Current Ratio | 4.23+0.6 | 3.67-0.9 | 4.61-1.7 | 6.34-1.0 | 7.37-1.8 | 9.21-0.2 | 9.45+2.2 | 7.27 |
| Debt-to-Equity | 0.42+0.0 | 0.39+0.1 | 0.30+0.1 | 0.22+0.0 | 0.18+0.0 | 0.15+0.0 | 0.14+0.1 | 0.00 |
| FCF Margin | -116.4%+22.2pp | -138.6%-8.4pp | -130.2%+26.2pp | -156.5%+8.9pp | -165.3%+22.7pp | -188.0%+158.4pp | -346.5%-61.5pp | -285.0% |
Similar Companies
Frequently Asked Questions
What is Rapid Micro Biosystems, Inc.'s annual revenue?
Rapid Micro Biosystems, Inc. (RPID) reported $28.1M in total revenue for fiscal year 2024. This represents a 24.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Rapid Micro Biosystems, Inc.'s revenue growing?
Rapid Micro Biosystems, Inc. (RPID) revenue grew by 24.6% year-over-year, from $22.5M to $28.1M in fiscal year 2024.
Is Rapid Micro Biosystems, Inc. profitable?
No, Rapid Micro Biosystems, Inc. (RPID) reported a net income of -$46.9M in fiscal year 2024, with a net profit margin of -167.2%.
What is Rapid Micro Biosystems, Inc.'s earnings per share (EPS)?
Rapid Micro Biosystems, Inc. (RPID) reported diluted earnings per share of $-1.08 for fiscal year 2024. This represents a 11.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Rapid Micro Biosystems, Inc.'s EBITDA?
Rapid Micro Biosystems, Inc. (RPID) had EBITDA of -$46.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Rapid Micro Biosystems, Inc. have?
As of fiscal year 2024, Rapid Micro Biosystems, Inc. (RPID) had $16.9M in cash and equivalents against $0 in long-term debt.
What is Rapid Micro Biosystems, Inc.'s operating margin?
Rapid Micro Biosystems, Inc. (RPID) had an operating margin of -178.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Rapid Micro Biosystems, Inc.'s net profit margin?
Rapid Micro Biosystems, Inc. (RPID) had a net profit margin of -167.2% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Rapid Micro Biosystems, Inc.'s free cash flow?
Rapid Micro Biosystems, Inc. (RPID) generated -$45.5M in free cash flow during fiscal year 2024. This represents a 3.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Rapid Micro Biosystems, Inc.'s operating cash flow?
Rapid Micro Biosystems, Inc. (RPID) generated -$44.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Rapid Micro Biosystems, Inc.'s total assets?
Rapid Micro Biosystems, Inc. (RPID) had $98.2M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Rapid Micro Biosystems, Inc.'s capital expenditures?
Rapid Micro Biosystems, Inc. (RPID) invested $1.4M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Rapid Micro Biosystems, Inc. spend on research and development?
Rapid Micro Biosystems, Inc. (RPID) invested $14.6M in research and development during fiscal year 2024.
What is Rapid Micro Biosystems, Inc.'s current ratio?
Rapid Micro Biosystems, Inc. (RPID) had a current ratio of 4.61 as of fiscal year 2024, which is generally considered healthy.
What is Rapid Micro Biosystems, Inc.'s debt-to-equity ratio?
Rapid Micro Biosystems, Inc. (RPID) had a debt-to-equity ratio of 0.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Rapid Micro Biosystems, Inc.'s return on assets (ROA)?
Rapid Micro Biosystems, Inc. (RPID) had a return on assets of -47.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Rapid Micro Biosystems, Inc.'s cash runway?
Based on fiscal year 2024 data, Rapid Micro Biosystems, Inc. (RPID) had $16.9M in cash against an annual operating cash burn of $44.2M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Rapid Micro Biosystems, Inc.'s Piotroski F-Score?
Rapid Micro Biosystems, Inc. (RPID) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Rapid Micro Biosystems, Inc.'s earnings high quality?
Rapid Micro Biosystems, Inc. (RPID) has an earnings quality ratio of 0.94x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Rapid Micro Biosystems, Inc.?
Rapid Micro Biosystems, Inc. (RPID) scores 60 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.